AceAge is a healthcare technology company focused on enhancing health outcomes for aging individuals through innovative products. The company's flagship product, Karie, is a home health appliance designed to help users manage their medication routines effectively. Karie organizes, schedules, and dispenses pills with one-button control, addressing the critical issue of medication nonadherence, which costs the U.S. healthcare system approximately $290 billion annually. By automating daily medication routines, Karie minimizes human error and supports greater patient autonomy, ultimately improving compliance with prescribed medical directions. The device utilizes common multi-dose pouch packaging that can be pre-set by pharmacists, ensuring that doses are delivered and monitored accurately. Through its user-friendly design, AceAge aims to enhance patient health while reducing the necessity for emergency care visits and assisted living admissions.
Triumvira Immunologics is an immunotherapy company focused on developing innovative T cell therapies for cancer treatment. Founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada, the company specializes in chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Its proprietary T cell Antigen Coupler (TAC) technology enhances the natural T cell receptor's capabilities and operates independently of the major histocompatibility complex. This unique approach aims to create more effective therapies for a diverse group of patients suffering from both solid and liquid tumors, as well as other diseases. Triumvira's commitment to advancing cancer treatment reflects its mission to improve patient outcomes with safer and more effective therapeutic options.
Antibe Therapeutics Inc. is a pharmaceutical development company based in Toronto, Canada, focusing on novel therapeutics and medical devices targeting pain, inflammation, and regenerative medicine. The company aims to enhance existing drugs to prevent gastrointestinal damage associated with non-steroidal anti-inflammatory drugs. Its lead compound, ATB-346, is a hydrogen sulfide-releasing derivative of naproxen, designed for the treatment of rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, having successfully completed a Phase 2B gastrointestinal safety study. Antibe is also developing ATB-352, currently in preclinical stages for gout and dental pain, and ATB-340, which targets stroke and cancer. Additionally, the company offers various products for the dental and orthopedic markets, including bone graft substitutes and barrier membranes. Antibe’s research and development efforts are supported by a team of distinguished pharmaceutical researchers, including a Nobel Prize winner, who are committed to exploring the therapeutic potential of hydrogen sulfide as a treatment modality.
Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on developing and commercializing innovative treatments for infectious diseases. Founded in 2015, the company has an anti-infective portfolio that includes several key candidates: Favipiravir, aimed at addressing pandemic influenza and COVID-19; ATI-2307, an antifungal agent in clinical development for cryptococcal meningitis and invasive candidiasis; and ATI-1501, an oral liquid formulation of metronidazole. Additionally, Appili is advancing ATI-1503, which targets gram-negative bacteria, and ATI-1701, a live-attenuated vaccine designed for Francisella tularensis. The company seeks to address unmet medical needs through improved therapies and the development of new classes of anti-infectives.
HLS is dedicated to the stewardship of branded pharmaceuticals through their life cycles post - exclusivity. HLS ensures the availability of treatments critical to patients and their caregivers with the brand names they trust.
Hamilton Thorne, Inc. is a leading provider of advanced laser systems and instruments for in-vitro cell applications in the regenerative medicine research and fertility clinic markets. Hamilton Thorne's ZILOS-tk and XYClone laser systems attach to standard inverted microscopes and operate as robotic micro-surgeons, reducing time and increasing efficiency in key stem cell, embryo and living cell procedures. Hamilton Thorne's CASA systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the animal, human infertility and reproductive toxicology fields. The Company's novel laser systems are rapidly emerging as the dominant products to facilitate precise micro-surgical procedures with stem cells and other living cells in the laboratory. Specific applications include the reduction from nine months to six weeks to develop transgenic animal models, dramatic reductions in cell damage during micro-surgical procedures and 50% higher yields for many cell procedures. The Company sells its products to pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Hamilton Thorne's current customers include some of the leading research labs in the world, including Harvard University, MIT, Yale, Dupont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.
Bellus Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, focused on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. Additionally, the company is advancing KIACTA™, a novel treatment for AA amyloidosis and sarcoidosis, both rare diseases affecting renal and pulmonary functions, respectively. KIACTA™ is in the data review stage following a Phase 3 study. Bellus Health is also developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies in progress. Furthermore, the company has a research-stage project aimed at treating AL amyloidosis, a condition characterized by the accumulation of amyloid proteins in various organs. Bellus Health is dedicated to addressing unmet medical needs through its innovative drug development pipeline.
Knight Therapeutics Inc. is a Montreal-based specialty pharmaceutical company engaged in the development, acquisition, in-licensing, and distribution of pharmaceutical and consumer health products, as well as medical devices, both in Canada and internationally. The company markets several products, including Movantik for opioid-induced constipation, Neuragen for pain associated with neuropathy, and Mytesi for noninfectious diarrhea in adults with HIV or AIDS. Additionally, it has a diverse pipeline that includes therapies for conditions such as opioid addiction, chronic pain, diabetic macular edema, and various cancers. Knight Therapeutics also invests in life sciences and finances other companies within the sector. Founded in 2013, the company aims to bring innovative healthcare solutions to the market and improve patient outcomes.
Newtopia Inc. is a health technology company based in Toronto, Canada, that focuses on habit change to address metabolic risk reduction. Founded in 2008, Newtopia operates a proprietary virtual platform that creates personalized health plans by integrating genetic, social, and psychological insights. The company aims to tackle the widespread issue of unhealthy lifestyles, which contribute to obesity, chronic diseases, and aging. Newtopia's innovative health engagement platform encourages individuals to adopt healthier lifestyle choices, demonstrating a successful model with an 80% success rate among beta clients. By partnering with insurers, self-insured employers, and brands, Newtopia seeks to deliver sustainable health outcomes and generate a meaningful return on investment, targeting the growing demand for effective wellness solutions in the corporate sector.
Noden Pharma is a global specialty pharmaceutical company dedicated to acquiring and marketing prescription medicines across various therapeutic areas. The company holds exclusive worldwide rights to manufacture and sell Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor used in the treatment of hypertension. By focusing on international markets, Noden Pharma aims to enhance the lives of patients through effective medical solutions.
Knight Therapeutics Inc. is a Montreal-based specialty pharmaceutical company engaged in the development, acquisition, in-licensing, and distribution of pharmaceutical and consumer health products, as well as medical devices, both in Canada and internationally. The company markets several products, including Movantik for opioid-induced constipation, Neuragen for pain associated with neuropathy, and Mytesi for noninfectious diarrhea in adults with HIV or AIDS. Additionally, it has a diverse pipeline that includes therapies for conditions such as opioid addiction, chronic pain, diabetic macular edema, and various cancers. Knight Therapeutics also invests in life sciences and finances other companies within the sector. Founded in 2013, the company aims to bring innovative healthcare solutions to the market and improve patient outcomes.
Tribute Pharmaceuticals is a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market. Tribute Pharmaceuticals has two facilities located in Milton, Ontario and London, Ontario and takes great pride in its employees, sales representatives and authorized third parties providers. Our mission is to offer quality healthcare products that treat recognized medical conditions and diseases. Tribute is committed to providing patients and physicians with clinically proven pharmaceuticals products that have been approved by regulatory authorities in Canada and other parts of the world.
Hamilton Thorne, Inc. is a leading provider of advanced laser systems and instruments for in-vitro cell applications in the regenerative medicine research and fertility clinic markets. Hamilton Thorne's ZILOS-tk and XYClone laser systems attach to standard inverted microscopes and operate as robotic micro-surgeons, reducing time and increasing efficiency in key stem cell, embryo and living cell procedures. Hamilton Thorne's CASA systems are designed to bring quality, efficiency and reliability to studies of reproductive cells in the animal, human infertility and reproductive toxicology fields. The Company's novel laser systems are rapidly emerging as the dominant products to facilitate precise micro-surgical procedures with stem cells and other living cells in the laboratory. Specific applications include the reduction from nine months to six weeks to develop transgenic animal models, dramatic reductions in cell damage during micro-surgical procedures and 50% higher yields for many cell procedures. The Company sells its products to pharmaceutical companies, biotechnology companies, fertility clinics, university research centers and other commercial and academic research establishments worldwide. Hamilton Thorne's current customers include some of the leading research labs in the world, including Harvard University, MIT, Yale, Dupont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University and Cambridge.
Profound Medical Corp. is a medical technology company that specializes in the development of magnetic resonance guided ablation procedures for treating conditions such as prostate disease, uterine fibroids, and palliative pain from bone metastases. The company's lead product, the TULSA-PRO system, combines real-time MRI guidance with robotically driven ultrasound to provide precise, non-invasive tissue ablation. This system is designed to work seamlessly with existing MRI infrastructure in hospitals and treatment facilities. Additionally, Profound Medical offers the Sonalleve platform, which targets uterine fibroids and bone metastases. The company is headquartered in Mississauga, Canada, and has established a co-development agreement with GE Healthcare to enhance access to its TULSA-PRO system. Profound Medical is committed to improving patient care by providing safe and effective treatment options that allow for quicker recovery and a return to daily activities.
Knight Therapeutics Inc. is a Montreal-based specialty pharmaceutical company engaged in the development, acquisition, in-licensing, and distribution of pharmaceutical and consumer health products, as well as medical devices, both in Canada and internationally. The company markets several products, including Movantik for opioid-induced constipation, Neuragen for pain associated with neuropathy, and Mytesi for noninfectious diarrhea in adults with HIV or AIDS. Additionally, it has a diverse pipeline that includes therapies for conditions such as opioid addiction, chronic pain, diabetic macular edema, and various cancers. Knight Therapeutics also invests in life sciences and finances other companies within the sector. Founded in 2013, the company aims to bring innovative healthcare solutions to the market and improve patient outcomes.
Newtopia Inc. is a health technology company based in Toronto, Canada, that focuses on habit change to address metabolic risk reduction. Founded in 2008, Newtopia operates a proprietary virtual platform that creates personalized health plans by integrating genetic, social, and psychological insights. The company aims to tackle the widespread issue of unhealthy lifestyles, which contribute to obesity, chronic diseases, and aging. Newtopia's innovative health engagement platform encourages individuals to adopt healthier lifestyle choices, demonstrating a successful model with an 80% success rate among beta clients. By partnering with insurers, self-insured employers, and brands, Newtopia seeks to deliver sustainable health outcomes and generate a meaningful return on investment, targeting the growing demand for effective wellness solutions in the corporate sector.
Knight Therapeutics Inc. is a Montreal-based specialty pharmaceutical company engaged in the development, acquisition, in-licensing, and distribution of pharmaceutical and consumer health products, as well as medical devices, both in Canada and internationally. The company markets several products, including Movantik for opioid-induced constipation, Neuragen for pain associated with neuropathy, and Mytesi for noninfectious diarrhea in adults with HIV or AIDS. Additionally, it has a diverse pipeline that includes therapies for conditions such as opioid addiction, chronic pain, diabetic macular edema, and various cancers. Knight Therapeutics also invests in life sciences and finances other companies within the sector. Founded in 2013, the company aims to bring innovative healthcare solutions to the market and improve patient outcomes.
Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company based in Calgary, Canada, focused on the discovery and development of innovative treatments for cancer. Its primary product, pelareorep, is an immuno-oncology therapeutic derived from reovirus, designed to target solid tumors and hematological malignancies by enhancing the immune system's ability to combat cancer. The company has established collaboration agreements with prominent partners, including Merck KGaA and Pfizer, to explore combinations of pelareorep with other treatments, such as paclitaxel and avelumab, particularly for hormone-receptor positive, HER2-negative metastatic breast cancer. Oncolytics Biotech is also advancing additional projects in its pipeline, including treatments aimed at gastrointestinal cancers and breast cancer. Founded in 1998, the company continues to strive for breakthroughs in cancer therapeutics.